Overall, the arthritis pain treatment drug 2029 market outlook is highly attractive, driven by a projected CAGR of 7.4% and an expanding patient base exceeding 55 million in North America alone. Competitive intensity is moderate; a handful of legacy biologics dominate, yet several midsized firms are advancing selective‑COX‑2 inhibitors and gene‑silencing modalities, creating a fragmented yet opportunistic field. Long‑term outlook remains positive as aging demographics and rising obesity rates sustain demand, while payer reforms gradually improve reimbursement pathways for innovative therapies. The innovation landscape is vibrant, with three late‑stage pipeline candidates leveraging nanocarrier delivery and two CRISPR‑based approaches entering Phase II, suggesting a shift toward precision pain management. Supply is expected to keep pace, given capacity expansions at major contract manufacturers, though raw‑material bottlenecks for specialty polymers could tighten the balance in 2029. Key risks include regulatory delays for novel mechanisms, potential price‑cap legislation in major markets, and macro‑economic volatility that could curb healthcare spending.
